Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

87.87 -4.44 (-4.81%)
Official Closing Price Updated: 7:00 PM EDT, Mar 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 20,640,233
Open 92.31
Bid (Size) 87.98 (6)
Ask (Size) 88.04 (1)
Prev. Close 92.31
Today's Range 87.08 - 92.31
52wk Range 81.04 - 134.63
Shares Outstanding 2,531,374,696
Dividend Yield 3.51%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Gamestop, FST Corp, Merck, UPS, And Tesla: Why These 5 Stocks Are On Investors' Radars Today
The U.S. stock market had a mixed session on Tuesday. The Nasdaq Composite climbed nearly 80 points, or 0.5%, closing at 18,271.86, while the Dow remained largely flat at 42,587.50. The S&P 500 edged... 
Via Benzinga
Topics Stocks
Exposures US Equities
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against FMC, TransMedics, Alarum, and Merck and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire

Performance

YTD
-11.4%
-11.4%
1 Month
-3.7%
-3.7%
3 Month
-11.6%
-11.6%
6 Month
-23.6%
-23.6%
1 Year
-29.9%
-29.9%

More News

Read More
Why Pharma and Biotech Stocks Got Thrashed on Tuesday
Via The Motley Fool
What's going on in today's session: S&P500 movers
Via Chartmill
Tuesday's session: top gainers and losers in the S&P500 index
Via Chartmill
Merck Enters $2B License Agreement With China-Based Hengrui Pharma For Heart Disease Drug: Retail’s Unswayed
Via Stocktwits
Merck Partners With Hengrui Pharma In $1.77 Billion Deal For Cardiovascular Treatment
Via Benzinga
Mural Oncology's Ovarian Cancer Combo Drug Trial Disappoints, Stock Plunges
Via Benzinga
Merck Enters Exclusive License Agreement for HRS-5346, an Investigational Oral Lipoprotein(a) Inhibitor, for Cardiovascular Disease from Jiangsu Hengrui Pharmaceuticals Co., Ltd.
From Merck & Co., Inc.
Via Business Wire
Analyst Initiates Coverage On 'Undervalued' Summit Therapeutics
Via Benzinga
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co.
From Faruqi & Faruqi, LLP
Via Business Wire
Which S&P500 stocks are gapping on Monday?
Via Chartmill
MERCK & CO., INC. (NYSE: MRK) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Merck & Co., Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
1 Value Stock with Solid Fundamentals and 2 to Turn Down
Via StockStory
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co.
From Faruqi & Faruqi LLP
Via GlobeNewswire
2 Beaten-Down Stocks to Buy on the Dip
Via The Motley Fool
“We’re In A Stock Pickers Market”
Via Talk Markets
Topics ETFs
Which Is The Healthiest Investment: Merck Or Pfizer
Via Talk Markets
Topics Stocks / Equities
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed
Via Benzinga
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against FMC, TransMedics, Alarum, and Merck and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRK
From The Rosen Law Firm PA
Via GlobeNewswire
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co.
From Faruqi & Faruqi LLP
Via GlobeNewswire
Merck Data at ACC.25 Highlight Innovative Advancements and Commitment to Improving Outcomes for People Living with Cardiovascular Disease
From Merck & Co., Inc.
Via Business Wire
Merck & Co's Options: A Look at What the Big Money is Thinking
Via Benzinga
Pliant Therapeutics' Investigational Cancer Drug Shows Antitumor Activity Across Multiple Tumor Types
Via Benzinga

Frequently Asked Questions

Is Merck & Co publicly traded?
Yes, Merck & Co is publicly traded.
What exchange does Merck & Co trade on?
Merck & Co trades on the New York Stock Exchange
What is the ticker symbol for Merck & Co?
The ticker symbol for Merck & Co is MRK on the New York Stock Exchange
What is the current price of Merck & Co?
The current price of Merck & Co is 87.87
When was Merck & Co last traded?
The last trade of Merck & Co was at 03/25/25 07:00 PM ET
What is the market capitalization of Merck & Co?
The market capitalization of Merck & Co is 222.43B
How many shares of Merck & Co are outstanding?
Merck & Co has 222B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.